Chemosis

Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting

Retrieved on: 
Thursday, April 20, 2023
Science, Biotechnology, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Hypersensitivity, Meibomian gland, Fetus, Safety, Cataract, Fungus, Dose, Development, Floater, Data analysis, Photophobia, Patient, Risk, Macular edema, Association for Research in Vision and Ophthalmology, Virus, NYSE, Chickenpox, Canker, ARVO, Pregnancy, Conjunctiva, Photopsia, Viral, HPA, Chemosis, Intraocular pressure, Administration, Uveitis, Bacteria, Chalazion, Hypothalamic–pituitary hormone, FDA, Lomb, Hyperglycemia, Perception, Efficacy, Eye, History, Sanfilippo, ARMOR, Triamcinolone, Cover My Eyes (Pain and Heaven), Intraocular lens, Glaucoma, Cornea, Research and development, Nursing, Telecanthus, Vaccinia, Asbell, Bausch & Lomb, Meibomian gland dysfunction, Visual acuity, Pharmaceutical industry, Wood drying, Vaccine, Telescopic sight, Dietary supplement, Ophthalmology, Kalahari Desert

“Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.

Key Points: 
  • “Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.
  • “Early Adoption of Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Physician Survey.” Chang et al.
  • “Longitudinal Analysis of In Vitro Antibiotic Resistance Among Ocular Staphylococci Collected in the ARMOR study.” Asbell et al.
  • To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch .

Bausch + Lomb Announces Scientific Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting

Retrieved on: 
Wednesday, July 6, 2022
Suprachoroidal drug delivery, Canadian Securities Administrators, Patient, SCS, Canker, COVID-19, Hypersensitivity, Bausch & Lomb, Bacteria, Lens (anatomy), Floater, Uveitis, Degenerative disease, Pregnancy, Fetus, FDA, Dose, Triamcinolone, ASRS, Conjunctiva, Cataract, Nursing, Hypothalamic–pituitary hormone, Macular edema, NYSE, Cushing's syndrome, Cornea, Instagram, Twitter, Eye, LinkedIn, Administration, Duane syndrome, HPA, Virus, Chickenpox, News, Chalazion, Chemosis, U.S. Securities and Exchange Commission, History, Photophobia, Meibomian gland, Glaucoma, Fungus, Risk, Vaccinia, Cover My Eyes (Pain and Heaven), Visual acuity, Intraocular pressure, Facebook, Fear, Society, Photopsia, Hyperglycemia, Pharmaceutical industry, Silviculture, Vaccine, Telescopic sight

VAUGHAN, ON, July 6, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that five presentations highlighting data from the XIPERE® (triamcinolone acetonide injectable suspension) pivotal Phase 3 program will be presented at the American Society of Retina Specialists (ASRS) 40th annual scientific meeting, which will take place in New York from July 13-16, 2022. The presentations will include a new post-hoc analysis of the pivotal Phase 3 trial (PEACHTREE) evaluating outcomes following treatment with XIPERE® in patients with macular edema associated with chronic uveitis.

Key Points: 
  • "At this year's ASRS annual meeting, we look forward to sharing these data with retina specialists on XIPERE, which we launched commercially in March," said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb.
  • Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with uveitis: Outcomes by anatomic subtypes in PEACHTREE.
  • Efficacy of suprachoroidal triamcinolone acetonide injectable suspension in the treatment of macular edema in patients with chronic uveitis.
  • XIPERE(triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

Amneal Receives Approval for Difluprednate Ophthalmic Emulsion

Retrieved on: 
Friday, November 19, 2021
Research, FDA, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Optical, Science, Other Science, Glaucoma, ANDA, Security (finance), Visual acuity, Regulation of tobacco by the U.S. Food and Drug Administration, Common stock, Annual report, Disulfiram-like drug, Chemosis, Private Securities Litigation Reform Act, Forward-looking statement, Company, NYSE, Blepharitis, Canker, Inflammation, Weather, Central nervous system, Degenerative disease, Munitions Safety Information Analysis Center, U.S. Securities and Exchange Commission, Eye, COVID-19, Pain, Abbreviated New Drug Application, Conjunctiva, Federation, Investment, Risk, Research, Incidence, Cover My Eyes (Pain and Heaven), Optic nerve, Ownership, FDA, Cornea, Medication, Growth, Food, Risk management

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for difluprednate ophthalmic emulsion 0.05%, which is the generic version of Durezol and is used in the treatment of inflammation and pain associated with ocular surgery.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for difluprednate ophthalmic emulsion 0.05%, which is the generic version of Durezol and is used in the treatment of inflammation and pain associated with ocular surgery.
  • With the approval of difluprednate, a complex ophthalmic suspension product, we continue to shift our portfolio to increasingly complex and more differentiated product areas.
  • Difluprednate Ophthalmic Emulsion, 0.05%, as with other ophthalmic corticosteroids, may result in posterior subcapsular cataract formation; increase the hazard of secondary ocular infections, and delay healing with the increase in the incidence of bleb formation.
  • Difluprednate use is contraindicated in fungal disease of ocular structures; viral diseases of the cornea and conjunctiva; and Mycobacterial infection of the eye.